HOWL · Werewolf Therapeutics, Inc.
$0.35
-0.15 (-29.38%)
At close · Jul 31
Going-concern doubt
— flagged Jul 31, 2026
Substantial doubt about the company's ability to continue as a going concern.
“We believe there is substantial doubt about our ability to continue as a going concern for at least twelve months from the date that these condensed consolidated financial statements are issued in this Quarterly Report.”View the 10-Q filed Jul 31, 2026
Market Cap
$17.16M
Shares
48.60M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.35
Open$0.50
Day$0.34–0.50
52W$0.27–2.38
Avg vol 30d940K
Short int934K · 1.9% float · 1.0d
Short vol43%
DataApr 2021–Jul 2026
Filing10-Q · Jul 31
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 31, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Bearish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.63
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−53%
below
Price vs 50-day avg
−9%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+4%
trailing
6-month return
−42%
trailing
YTD return
−44%
this year
Relative strength
−50%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
4 of 48 funds reported for Jun 30 · net -4.5K sh shares
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Rising
1.92% of float · ▲ +10.3% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
48 holders — mid 3-yr range
Squeeze score
48
elevated · 0–100
Fundamentals
EPS growth
+18%
Y/Y
Free cash flow
$-60.3M
Balance sheet
$25.0M
net cash
Quant / Vol
risk profile
Volatility
103%
annualized · 1-yr
Max drawdown
−86%
past year
ATR
15.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−53%
Bearish
Price vs 50-day avg
−9%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross)
No cross
50d $0 › 200d $1 — 200d above 50d
Institutional flow
Distributing
4 of 48 funds reported for Jun 30 · net -4.5K sh shares
Insider flow
Distributing
Net -$1.7M over 90 days · 100% sells
Short interest
Rising
1.92% of float · ▲ +10.3% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
48 holders — mid 3-yr range
Price context
position in its 52-week range
52-wk low $0
Now $0 · 4%
52-wk high $2
vs 200-day avg -53%
vs 50-day avg -9%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HOWL
this stock
Werewolf Therapeutics, Inc.
|
$17.16M | -44.3% | — | — | 1.9% |
|
ONC
BeOne Medicines Ltd.
|
$456.72B | +4.0% | +22179.2% | 929.4 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$121.09B | +5.2% | +46.2% | 28.3 | 2.0% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$78.52B | -1.1% | +20.8% | 18.9 | 3.4% |
|
ARGX
Argenx SE
|
$53.42B | +1.5% | — | — | 2.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HOWL | -17.3% | +3.9% | -42.3% | -1.9% | -44.3% |
| SPY | +1.1% | +0.3% | +8.2% | +0.0% | +9.6% |
| vs SPY | -18.4% | +3.6% | -50.5% | -2.0% | -53.9% |